Literature DB >> 11572869

MDM2 can promote the ubiquitination, nuclear export, and degradation of p53 in the absence of direct binding.

T Inoue1, R K Geyer, D Howard, Z K Yu, C G Maki.   

Abstract

MDM2 can bind the N terminus of p53 and promote its ubiquitination and export from the nucleus to the cytoplasm, where p53 can then be degraded by cytoplasmic proteasomes. Several studies have reported that an intact MDM2 binding domain is necessary for p53 to be targeted for ubiquitination, nuclear export, and degradation by MDM2. In the current study, we examined whether the MDM2 binding domain of p53 could be provided in trans through oligomerization between two p53 molecules. p53 proteins mutated in their MDM2 binding domains were unable to bind MDM2 directly and were resistant to MDM2-mediated ubiquitination, nuclear export, and degradation when expressed with MDM2 alone. However, these same p53 mutants formed a complex with MDM2 and were efficiently ubiquitinated, exported from the nucleus, and degraded when co-expressed with MDM2 and wild-type p53. Moreover, this effect required MDM2 binding by wild-type p53 as well as oligomerization between wild-type p53 and the MDM2 binding-deficient p53 mutants. Taken together, these results support a model whereby MDM2 binding-deficient forms of p53 can bind MDM2 indirectly through oligomerization with wild-type p53 and are subsequently targeted for ubiquitination, nuclear export, and degradation. These findings may have important implications regarding the DNA damage response of p53.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11572869     DOI: 10.1074/jbc.M107477200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  23 in total

1.  Substrate phosphorylation and feedback regulation in JFK-promoted p53 destabilization.

Authors:  Luyang Sun; Lei Shi; Feng Wang; Peiwei Huangyang; Wenzhe Si; Jie Yang; Zhi Yao; Yongfeng Shang
Journal:  J Biol Chem       Date:  2010-12-02       Impact factor: 5.157

Review 2.  Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies.

Authors:  Zijun Y Xu-Monette; L Jeffrey Medeiros; Yong Li; Robert Z Orlowski; Michael Andreeff; Carlos E Bueso-Ramos; Timothy C Greiner; Timothy J McDonnell; Ken H Young
Journal:  Blood       Date:  2012-01-24       Impact factor: 22.113

3.  Identification and characterization of two novel isoforms of Pirh2 ubiquitin ligase that negatively regulate p53 independent of RING finger domains.

Authors:  Chad A Corcoran; JoAnne Montalbano; Hong Sun; Qin He; Ying Huang; M Saeed Sheikh
Journal:  J Biol Chem       Date:  2009-05-29       Impact factor: 5.157

4.  E3 ligases determine ubiquitination site and conjugate type by enforcing specificity on E2 enzymes.

Authors:  Yael David; Nicola Ternette; Mariola J Edelmann; Tamar Ziv; Batya Gayer; Rotem Sertchook; Yakir Dadon; Benedikt M Kessler; Ami Navon
Journal:  J Biol Chem       Date:  2011-09-30       Impact factor: 5.157

5.  Hypoxia-induced assembly of prolyl hydroxylase PHD3 into complexes: implications for its activity and susceptibility for degradation by the E3 ligase Siah2.

Authors:  Koh Nakayama; Stefan Gazdoiu; Robert Abraham; Zhen-Qiang Pan; Ze'ev Ronai
Journal:  Biochem J       Date:  2007-01-01       Impact factor: 3.857

6.  Post-translational modification of cyclin A1 is associated with staurosporine and TNFalpha induced apoptosis in leukemic cells.

Authors:  Jenny Ekberg; Jenny Liao Persson
Journal:  Mol Cell Biochem       Date:  2008-09-12       Impact factor: 3.396

7.  Impaired p53 expression, function, and nuclear localization in calreticulin-deficient cells.

Authors:  Nasrin Mesaeli; Clark Phillipson
Journal:  Mol Biol Cell       Date:  2004-02-06       Impact factor: 4.138

8.  MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program.

Authors:  Zijun Y Xu-Monette; Michael B Møller; Alexander Tzankov; Santiago Montes-Moreno; Wenwei Hu; Ganiraju C Manyam; Louise Kristensen; Lei Fan; Carlo Visco; Karen Dybkaer; April Chiu; Wayne Tam; Youli Zu; Govind Bhagat; Kristy L Richards; Eric D Hsi; William W L Choi; J Han van Krieken; Qin Huang; Jooryung Huh; Weiyun Ai; Maurilio Ponzoni; Andrés J M Ferreri; Lin Wu; Xiaoying Zhao; Carlos E Bueso-Ramos; Sa A Wang; Ronald S Go; Yong Li; Jane N Winter; Miguel A Piris; L Jeffrey Medeiros; Ken H Young
Journal:  Blood       Date:  2013-08-27       Impact factor: 22.113

9.  Geldanamycin promotes premature mitotic entry and micronucleation in irradiated p53/p21 deficient colon carcinoma cells.

Authors:  D M Moran; G Gawlak; M S Jayaprakash; S Mayar; C G Maki
Journal:  Oncogene       Date:  2008-05-26       Impact factor: 9.867

10.  Puromycin-based vectors promote a ROS-dependent recruitment of PML to nuclear inclusions enriched with HSP70 and Proteasomes.

Authors:  Diarmuid M Moran; Hong Shen; Carl G Maki
Journal:  BMC Cell Biol       Date:  2009-05-01       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.